Badanie skuteczności leczenia neoadiuwantowego z pembrolizumabem i lenwatynibem u pacjentów z resekcyjnym czerniakiem błon śluzowych

The study focuses on a type of skin cancer called mucosal melanoma, which can be surgically removed. The main goal is to see how well patients do without the disease coming back after receiving a specific treatment. This treatment involves using a medicine called pembrolizumab, known by the brand name KEYTRUDA, which is given through an infusion into the vein. In some cases, another medicine called lenvatinib, known by the brand name LENVIMA, which is taken as a capsule, may also be used.

The study aims to compare the results of this treatment with past results from patients who only had surgery and possibly radiotherapy. The treatment plan includes giving pembrolizumab before surgery, and possibly lenvatinib, followed by surgery and radiotherapy if needed. After surgery, pembrolizumab is continued as a maintenance therapy to help prevent the cancer from returning.

The study will measure how long patients remain free of the disease over a period of two years. This will help determine if the combination of these treatments is more effective than previous methods. The study will also look at other factors like overall survival and how well the cancer responds to the treatment before surgery.